BACKGROUND	We prospectively measured VEGF in serum collected from patients enrolled in Cancer and Leukemia Group B 30203 , a randomized phase II study of eicosanoid modulation in addition to chemotherapy in patients with advanced NSCLC , to determine whether these levels had prognostic significance and whether they correlated with COX-2 expression and/or responded to inhibition of COX-2 or 5-LOX .\